bioMerieux (FR:BIM) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
bioMerieux has announced FDA authorization and CLIA waiver for its BIOFIRE SPOTFIRE R/ST Panel Mini, enhancing the ‘Point of Care’ market with rapid, sensitive testing for common respiratory viruses and streptococcal infections. This test, which provides results in about 15 minutes from a single sample, is set to be available in the U.S. from Q3 2024. It represents a significant advancement in delivering quick, accurate diagnoses and appropriate treatments at patient care sites.
For further insights into FR:BIM stock, check out TipRanks’ Stock Analysis page.